13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection

E. Giannini, A. Fasoli, B. Chiarbonello, F. Malfatti, P. Romagnoli, F. Botta, E. Testa, S. Polegato, A. Fumagalli, R. Testa

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background: There are few data on the use of the 13C-aminopyrine breath test to evaluate the severity of disease in patients with hepatitis C virus-related chronic liver disease, although these patients represent one of the most important problems in clinical hepatology. Aims: To compare 13C-aminopyrine breath test results of patients with hepatitis C virus-related chronic hepatitis and Child-Pugh class A cirrhosis with those of normal subjects, and to evaluate different methods of expressing 13C-aminopyrine breath test results. Methods: Twenty-four patients with hepatitis C virus-related chronic hepatitis and 17 patients with Child-Pugh class A cirrhosis underwent 13C-aminopyrine breath test. Breath samples were collected every 30 min up to 2 h after 13C-aminopyrine administration. 13C-Aminopyrine breath test results were expressed as a percentage of the administered dose of 13C recovered per hour (% dose/h) and the cumulative percentage of administered dose of 13C recovered over time (% dose cum). Nineteen healthy subjects served as controls. Patients with hepatitis C virus-related chronic hepatitis were divided into subgroups on the basis of histological staging and grading. Results: The 13C-aminopyrine breath test result (% dose/h) at 30 min was significantly different among the three subgroups of subjects (normal subjects, 11.5 ± 3.5; chronic hepatitis patients. 8.1 ± 4.1; cirrhosis patients. 5.0 ± 3.1: P <0.0005). Moreover, the differences between chronic hepatitis and cirrhosis patients were statistically significant (P <0.03). The fibrosis score showed a significant inverse correlation with the 13C-aminopyrine breath test result (% dose/h) at 30 min (rs = - 0.409, P = 0.05). The 13C-aminopyrine breath test result (% dose/h) at 30 min also allowed normal subjects and chronic hepatitis patients with low (≤ 2) or high (> 2) fibrosis scores to be distinguished. The 13C-aminopyrine breath test results (% dose cum) at 30. 60 and 90 min allowed discrimination between normal subjects and chronic hepatitis and cirrhosis patients. The 13C-aminopyrine breath test result (% dose cum) was also able to distinguish between normal subjects and chronic hepatitis patients with high but not low fibrosis scores. Both 13C-aminopyrine breath test results (% dose/h and % dose cum) at 120 min allowed the differentiation between normal subjects and chronic hepatitis patients with high (≥ 6) necro-inflammatory activity. Conclusions: In patients with hepatitis C virus-related chronic liver disease, the 13C-aminopyrine breath test proved to be safe and easy to perform, and was able to evaluate different degrees of liver function impairment which were partly correlated to clinical and histological evaluation. In future studies, 13C-aminopyrine breath test results should be expressed in a standardized fashion to permit comparison.

Original languageEnglish
Pages (from-to)717-725
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume16
Issue number4
DOIs
Publication statusPublished - 2002

Fingerprint

Aminopyrine
Breath Tests
Chronic Hepatitis C
Virus Diseases
Hepacivirus
Chronic Hepatitis
Fibrosis
Liver Diseases
Chronic Disease
Gastroenterology
Healthy Volunteers

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. / Giannini, E.; Fasoli, A.; Chiarbonello, B.; Malfatti, F.; Romagnoli, P.; Botta, F.; Testa, E.; Polegato, S.; Fumagalli, A.; Testa, R.

In: Alimentary Pharmacology and Therapeutics, Vol. 16, No. 4, 2002, p. 717-725.

Research output: Contribution to journalArticle

Giannini, E. ; Fasoli, A. ; Chiarbonello, B. ; Malfatti, F. ; Romagnoli, P. ; Botta, F. ; Testa, E. ; Polegato, S. ; Fumagalli, A. ; Testa, R. / 13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. In: Alimentary Pharmacology and Therapeutics. 2002 ; Vol. 16, No. 4. pp. 717-725.
@article{43fd45fe47024c3487dd9cbf5b19a403,
title = "13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection",
abstract = "Background: There are few data on the use of the 13C-aminopyrine breath test to evaluate the severity of disease in patients with hepatitis C virus-related chronic liver disease, although these patients represent one of the most important problems in clinical hepatology. Aims: To compare 13C-aminopyrine breath test results of patients with hepatitis C virus-related chronic hepatitis and Child-Pugh class A cirrhosis with those of normal subjects, and to evaluate different methods of expressing 13C-aminopyrine breath test results. Methods: Twenty-four patients with hepatitis C virus-related chronic hepatitis and 17 patients with Child-Pugh class A cirrhosis underwent 13C-aminopyrine breath test. Breath samples were collected every 30 min up to 2 h after 13C-aminopyrine administration. 13C-Aminopyrine breath test results were expressed as a percentage of the administered dose of 13C recovered per hour ({\%} dose/h) and the cumulative percentage of administered dose of 13C recovered over time ({\%} dose cum). Nineteen healthy subjects served as controls. Patients with hepatitis C virus-related chronic hepatitis were divided into subgroups on the basis of histological staging and grading. Results: The 13C-aminopyrine breath test result ({\%} dose/h) at 30 min was significantly different among the three subgroups of subjects (normal subjects, 11.5 ± 3.5; chronic hepatitis patients. 8.1 ± 4.1; cirrhosis patients. 5.0 ± 3.1: P <0.0005). Moreover, the differences between chronic hepatitis and cirrhosis patients were statistically significant (P <0.03). The fibrosis score showed a significant inverse correlation with the 13C-aminopyrine breath test result ({\%} dose/h) at 30 min (rs = - 0.409, P = 0.05). The 13C-aminopyrine breath test result ({\%} dose/h) at 30 min also allowed normal subjects and chronic hepatitis patients with low (≤ 2) or high (> 2) fibrosis scores to be distinguished. The 13C-aminopyrine breath test results ({\%} dose cum) at 30. 60 and 90 min allowed discrimination between normal subjects and chronic hepatitis and cirrhosis patients. The 13C-aminopyrine breath test result ({\%} dose cum) was also able to distinguish between normal subjects and chronic hepatitis patients with high but not low fibrosis scores. Both 13C-aminopyrine breath test results ({\%} dose/h and {\%} dose cum) at 120 min allowed the differentiation between normal subjects and chronic hepatitis patients with high (≥ 6) necro-inflammatory activity. Conclusions: In patients with hepatitis C virus-related chronic liver disease, the 13C-aminopyrine breath test proved to be safe and easy to perform, and was able to evaluate different degrees of liver function impairment which were partly correlated to clinical and histological evaluation. In future studies, 13C-aminopyrine breath test results should be expressed in a standardized fashion to permit comparison.",
author = "E. Giannini and A. Fasoli and B. Chiarbonello and F. Malfatti and P. Romagnoli and F. Botta and E. Testa and S. Polegato and A. Fumagalli and R. Testa",
year = "2002",
doi = "10.1046/j.1365-2036.2002.01200.x",
language = "English",
volume = "16",
pages = "717--725",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",

}

TY - JOUR

T1 - 13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection

AU - Giannini, E.

AU - Fasoli, A.

AU - Chiarbonello, B.

AU - Malfatti, F.

AU - Romagnoli, P.

AU - Botta, F.

AU - Testa, E.

AU - Polegato, S.

AU - Fumagalli, A.

AU - Testa, R.

PY - 2002

Y1 - 2002

N2 - Background: There are few data on the use of the 13C-aminopyrine breath test to evaluate the severity of disease in patients with hepatitis C virus-related chronic liver disease, although these patients represent one of the most important problems in clinical hepatology. Aims: To compare 13C-aminopyrine breath test results of patients with hepatitis C virus-related chronic hepatitis and Child-Pugh class A cirrhosis with those of normal subjects, and to evaluate different methods of expressing 13C-aminopyrine breath test results. Methods: Twenty-four patients with hepatitis C virus-related chronic hepatitis and 17 patients with Child-Pugh class A cirrhosis underwent 13C-aminopyrine breath test. Breath samples were collected every 30 min up to 2 h after 13C-aminopyrine administration. 13C-Aminopyrine breath test results were expressed as a percentage of the administered dose of 13C recovered per hour (% dose/h) and the cumulative percentage of administered dose of 13C recovered over time (% dose cum). Nineteen healthy subjects served as controls. Patients with hepatitis C virus-related chronic hepatitis were divided into subgroups on the basis of histological staging and grading. Results: The 13C-aminopyrine breath test result (% dose/h) at 30 min was significantly different among the three subgroups of subjects (normal subjects, 11.5 ± 3.5; chronic hepatitis patients. 8.1 ± 4.1; cirrhosis patients. 5.0 ± 3.1: P <0.0005). Moreover, the differences between chronic hepatitis and cirrhosis patients were statistically significant (P <0.03). The fibrosis score showed a significant inverse correlation with the 13C-aminopyrine breath test result (% dose/h) at 30 min (rs = - 0.409, P = 0.05). The 13C-aminopyrine breath test result (% dose/h) at 30 min also allowed normal subjects and chronic hepatitis patients with low (≤ 2) or high (> 2) fibrosis scores to be distinguished. The 13C-aminopyrine breath test results (% dose cum) at 30. 60 and 90 min allowed discrimination between normal subjects and chronic hepatitis and cirrhosis patients. The 13C-aminopyrine breath test result (% dose cum) was also able to distinguish between normal subjects and chronic hepatitis patients with high but not low fibrosis scores. Both 13C-aminopyrine breath test results (% dose/h and % dose cum) at 120 min allowed the differentiation between normal subjects and chronic hepatitis patients with high (≥ 6) necro-inflammatory activity. Conclusions: In patients with hepatitis C virus-related chronic liver disease, the 13C-aminopyrine breath test proved to be safe and easy to perform, and was able to evaluate different degrees of liver function impairment which were partly correlated to clinical and histological evaluation. In future studies, 13C-aminopyrine breath test results should be expressed in a standardized fashion to permit comparison.

AB - Background: There are few data on the use of the 13C-aminopyrine breath test to evaluate the severity of disease in patients with hepatitis C virus-related chronic liver disease, although these patients represent one of the most important problems in clinical hepatology. Aims: To compare 13C-aminopyrine breath test results of patients with hepatitis C virus-related chronic hepatitis and Child-Pugh class A cirrhosis with those of normal subjects, and to evaluate different methods of expressing 13C-aminopyrine breath test results. Methods: Twenty-four patients with hepatitis C virus-related chronic hepatitis and 17 patients with Child-Pugh class A cirrhosis underwent 13C-aminopyrine breath test. Breath samples were collected every 30 min up to 2 h after 13C-aminopyrine administration. 13C-Aminopyrine breath test results were expressed as a percentage of the administered dose of 13C recovered per hour (% dose/h) and the cumulative percentage of administered dose of 13C recovered over time (% dose cum). Nineteen healthy subjects served as controls. Patients with hepatitis C virus-related chronic hepatitis were divided into subgroups on the basis of histological staging and grading. Results: The 13C-aminopyrine breath test result (% dose/h) at 30 min was significantly different among the three subgroups of subjects (normal subjects, 11.5 ± 3.5; chronic hepatitis patients. 8.1 ± 4.1; cirrhosis patients. 5.0 ± 3.1: P <0.0005). Moreover, the differences between chronic hepatitis and cirrhosis patients were statistically significant (P <0.03). The fibrosis score showed a significant inverse correlation with the 13C-aminopyrine breath test result (% dose/h) at 30 min (rs = - 0.409, P = 0.05). The 13C-aminopyrine breath test result (% dose/h) at 30 min also allowed normal subjects and chronic hepatitis patients with low (≤ 2) or high (> 2) fibrosis scores to be distinguished. The 13C-aminopyrine breath test results (% dose cum) at 30. 60 and 90 min allowed discrimination between normal subjects and chronic hepatitis and cirrhosis patients. The 13C-aminopyrine breath test result (% dose cum) was also able to distinguish between normal subjects and chronic hepatitis patients with high but not low fibrosis scores. Both 13C-aminopyrine breath test results (% dose/h and % dose cum) at 120 min allowed the differentiation between normal subjects and chronic hepatitis patients with high (≥ 6) necro-inflammatory activity. Conclusions: In patients with hepatitis C virus-related chronic liver disease, the 13C-aminopyrine breath test proved to be safe and easy to perform, and was able to evaluate different degrees of liver function impairment which were partly correlated to clinical and histological evaluation. In future studies, 13C-aminopyrine breath test results should be expressed in a standardized fashion to permit comparison.

UR - http://www.scopus.com/inward/record.url?scp=0036005718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036005718&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2036.2002.01200.x

DO - 10.1046/j.1365-2036.2002.01200.x

M3 - Article

C2 - 11929389

AN - SCOPUS:0036005718

VL - 16

SP - 717

EP - 725

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 4

ER -